TNFRSF17 and lymphoma: In November 2023, the FDA released a statement regarding reports of malignancies of T-cell origin, both lymphomas and leukaemias, including CAR-positive cases, in patients who had been previously treated with either anti-CD19- or anti-BCMA-directed autologous CAR T-cell products.